anagliptin

Known as: Pyrazolo(1,5-a)pyrimidine-6-carboxamide, N-(2-((2-((2S)-2-cyano-1-pyrrolidinyl)-2-oxoethyl)amino)-2-methylpropyl)-2-methyl- 
An orally available, potent, selective inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. Compared to vildagliptin, anagliptin… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
AIMS/INTRODUCTION Dipeptidyl peptidase-4 inhibitors are used for treatment of patients with type 2 diabetes. In addition to… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2016
2016
BACKGROUND Inhibition of dipeptidyl peptidase-4 (DPP-4) has been proposed as a therapeutic target for type 2 diabetes (T2DM… (More)
Is this relevant?
2015
2015
Dipeptidyl peptidase IV (DPP-IV) expression in visceral adipose tissue is reportedly increased in obese patients, suggesting an… (More)
Is this relevant?
2015
2015
The single-crystal structure of anagliptin, N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2… (More)
Is this relevant?
2015
2015
OBJECTIVE The mechanism responsible for the lipid-lowering effect of dipeptidyl peptidase-4 (DPP-4) inhibitors remains unknown in… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Dipeptyl peptidase-4 (DPP-4) inhibitors modulate the progression of atherosclerosis. To gain insights into their mechanism of… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2013
2013
OBJECTIVE. Inflammatory bowel disease (IBD) is a chronic debilitating disease associated with severe damage to the intestinal… (More)
  • figure 1
  • table I
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2013
2013
The pharmacokinetic disposition of anagliptin, an orally active and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor was… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2013
2013
1. The disposition of anagliptin, an orally active, highly selective dipeptidyl peptidase-4 inhibitor, was investigated after a… (More)
Is this relevant?
2013
2013
OBJECTIVE Type 2 diabetes is a chronic metabolic disorder characterized by hyperglycemia with insulin resistance and impaired… (More)
Is this relevant?